TW202337495A - 用satralizumab治療自體免疫腦炎 - Google Patents

用satralizumab治療自體免疫腦炎 Download PDF

Info

Publication number
TW202337495A
TW202337495A TW112102365A TW112102365A TW202337495A TW 202337495 A TW202337495 A TW 202337495A TW 112102365 A TW112102365 A TW 112102365A TW 112102365 A TW112102365 A TW 112102365A TW 202337495 A TW202337495 A TW 202337495A
Authority
TW
Taiwan
Prior art keywords
encephalitis
administered
nmdar
individual
lgi1
Prior art date
Application number
TW112102365A
Other languages
English (en)
Chinese (zh)
Inventor
小澤孝俊
井田広顕
伊藤創
吉田俊介
吉莉安 史密斯
克萊姆斯 希恩 藍儂
蓋勒 克蘭傑史密特
比丁根 漢斯 克里斯蒂安 馮
包曼 漢娜 席柏
詹姆士 奧弗雷爾
莎蜜菈 拉詹
Original Assignee
日商中外製藥股份有限公司
瑞士商赫孚孟拉羅股份公司
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司, 瑞士商赫孚孟拉羅股份公司, 美商建南德克公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202337495A publication Critical patent/TW202337495A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112102365A 2022-01-19 2023-01-18 用satralizumab治療自體免疫腦炎 TW202337495A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19

Publications (1)

Publication Number Publication Date
TW202337495A true TW202337495A (zh) 2023-10-01

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112102365A TW202337495A (zh) 2022-01-19 2023-01-18 用satralizumab治療自體免疫腦炎

Country Status (11)

Country Link
US (1) US20250127891A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466018A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502891A (cg-RX-API-DMAC7.html)
KR (1) KR20240145472A (cg-RX-API-DMAC7.html)
CN (1) CN118900699A (cg-RX-API-DMAC7.html)
AU (1) AU2023209259A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243067A1 (cg-RX-API-DMAC7.html)
IL (1) IL314213A (cg-RX-API-DMAC7.html)
MX (1) MX2024008835A (cg-RX-API-DMAC7.html)
TW (1) TW202337495A (cg-RX-API-DMAC7.html)
WO (1) WO2023140269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
JPWO2020202839A1 (cg-RX-API-DMAC7.html) * 2019-03-29 2020-10-08

Also Published As

Publication number Publication date
AU2023209259A1 (en) 2024-07-18
WO2023140269A1 (en) 2023-07-27
IL314213A (en) 2024-09-01
EP4466018A4 (en) 2026-03-25
MX2024008835A (es) 2024-07-25
KR20240145472A (ko) 2024-10-07
US20250127891A1 (en) 2025-04-24
JP2025502891A (ja) 2025-01-28
CA3243067A1 (en) 2023-07-27
EP4466018A1 (en) 2024-11-27
CN118900699A (zh) 2024-11-05

Similar Documents

Publication Publication Date Title
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
CA2490186C (en) Method for the treatment of multiple sclerosis
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
US20220356261A1 (en) Treatment for sjögren's syndrome
JP2024521474A (ja) 皮膚筋炎(dm)を治療するための抗c5抗体の投与量及び投与
TW202233676A (zh) 使用抗cd19抗體治療自體免疫性疾病
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
HK40111127A (en) Treatment of autoimmune encephalitis with satralizumab
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
JP2022180487A (ja) Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
HK40107811A (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
KR20210060582A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
HK40117117A (en) Dosage regimens for treating multifocal motor neuropathy (mmn)
JP2018526404A (ja) 再発型の多発性硬化症を治療するための方法